You are here > News and publications

News and publications

Promethera Biosciences successfully enrolls twenty patients in its multicentric Phase I/II trial



Promethera Biosciences has conducted the trial in Belgium, France, United Kingdom, Italy and Israel, successfully treating twenty patients affected by very rare liver-based metabolic diseases


Mont-Saint-Guibert (Belgium) - November 12, 2013 – Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial. 


Promethera Biosciences is conducting a first-in-man trial with HepaStem in paediatric patients suffering from orphan diseases. This trial is a prospective, open label, multicenter Phase I/II clinical study involving Urea Cycle Disorders (UCD) and Crigler-Najjar (CN) syndrome paediatric patients.



Télécharger ce fichier (FR)


Download this file (EN)







PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01